COMT and Parkinson disease: In a multicenter study of 197 PD patients, a significantly lower PNP prevalence was observed in PD patients co-administered with the COMT-inhibitor entacapone for at least 18 months (5.7%) compared to those without COMT-inhibitor under levodopa exposure for at least 3 years (19.4%) [73].